Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)

NCT00313209 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

933

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Roflumilast
DRUG: Placebo

Sponsor

AstraZeneca